R1	multi Arg1:T2 Arg2:T3	
R2	Has_value Arg1:T5 Arg2:T6	
R3	multi Arg1:T4 Arg2:T5	
R4	Has_qualifier Arg1:T7 Arg2:T4	
R5	Has_qualifier Arg1:T8 Arg2:T9	
*	OR T11 T10
R6	Has_qualifier Arg1:T11 Arg2:T12	
R7	Has_value Arg1:T15 Arg2:T16	
R8	Subsumes Arg1:T12 Arg2:T15	
R9	causal Arg1:T18 Arg2:T14	
R10	multi Arg1:T19 Arg2:T20	
R11	multi Arg1:T20 Arg2:T21	
R12	AND Arg1:T18 Arg2:T21	
R13	Has_value Arg1:T25 Arg2:T26	
R14	AND Arg1:T23 Arg2:T25	
R15	Has_qualifier Arg1:T27 Arg2:T28	
R16	AND Arg1:T24 Arg2:T27	
R17	Has_qualifier Arg1:T31 Arg2:T32	
R18	multi Arg1:T32 Arg2:T29	
R19	Has_negation Arg1:T32 Arg2:T30	
R20	Has_temporal Arg1:T33 Arg2:T34	
R21	Has_qualifier Arg1:T36 Arg2:T35	
R22	AND Arg1:T33 Arg2:T36	
R23	multi Arg1:T39 Arg2:T40	
R24	Has_temporal Arg1:T38 Arg2:T39	
R25	Has_qualifier Arg1:T42 Arg2:T41	
*	OR T43 T44
R26	AND Arg1:T43 Arg2:T42	
R27	Has_negation Arg1:T43 Arg2:T46	
R28	multi Arg1:T48 Arg2:T49	
R29	AND Arg1:T47 Arg2:T48	
R30	multi Arg1:T50 Arg2:T51	
R31	Has_value Arg1:T53 Arg2:T54	
R32	multi Arg1:T59 Arg2:T60	
R33	Has_value Arg1:T57 Arg2:T58	
R34	Has_value Arg1:T55 Arg2:T56	
R35	Has_temporal Arg1:T55 Arg2:T59	
R36	Has_value Arg1:T62 Arg2:T63	
R37	Has_value Arg1:T65 Arg2:T66	
R40	Has_negation Arg1:T70 Arg2:T71	
R41	Has_value Arg1:T75 Arg2:T74	
R38	Has_value Arg1:T70 Arg2:T69	
*	OR T70 T75
R39	AND Arg1:T68 Arg2:T70	
R42	AND Arg1:T67 Arg2:T70	
R43	Has_value Arg1:T79 Arg2:T80	
R44	Has_value Arg1:T77 Arg2:T78	
*	OR T77 T79
R45	Has_qualifier Arg1:T79 Arg2:T81	
R46	Has_qualifier Arg1:T77 Arg2:T81	
R47	Has_value Arg1:T84 Arg2:T83	
R48	Has_temporal Arg1:T57 Arg2:T59	
T1	Parsing_Error 0 79	Eligible patients must meet the following criteria to be enrolled in the study:
T2	Mood 84 99	Newly diagnosed
T3	Temporal 84 89	Newly
T4	Qualifier 101 109	stage IV
T5	Measurement 101 106	stage
T6	Value 107 109	IV
T7	Condition 110 135	squamous cell lung cancer
T8	Condition 190 200	metastases
T9	Qualifier 177 189	disseminated
T10	Condition 240 260	pericardial effusion
T11	Condition 229 236;252 260	pleural effusion
T12	Qualifier 219 228	malignant
T15	Measurement 295 317	6th TNM staging system
T16	Value 277 287	stage IIIB
T14	Procedure 357 373	adjuvant therapy
T18	Condition 378 401	early-stage lung cancer
T19	Temporal 418 469	at least 12 months have elapsed from that treatment
T20	Reference_point 455 469	that treatment
T21	Procedure 460 469	treatment
T23	Condition 500 536	squamous cell bronchogenic carcinoma
T25	Procedure 475 489	Histologically
T26	Value 490 499	confirmed
T24	Condition 568 600	mixed non-small cell histologies
T27	Condition 626 644	squamous carcinoma
T28	Qualifier 652 673	predominant histology
T29	Observation 693 723	small cell anaplastic elements
T30	Negation 728 731	not
T31	Condition 675 687	Mixed tumors
T32	Qualifier 693 723	small cell anaplastic elements
T33	Procedure 881 893	radiotherapy
T34	Temporal 872 880	previous
T35	Qualifier 920 936	locally advanced
T36	Condition 937 963	non-small cell lung cancer
T37	Non-representable 989 1050	the recurrence is outside the original radiation therapy port
T38	Procedure 1052 1069	Radiation therapy
T39	Temporal 1095 1146	>4 weeks prior to the initiation of study treatment
T40	Reference_point 1113 1146	the initiation of study treatment
T41	Qualifier 1195 1211	locally advanced
T42	Condition 1212 1217	NSCLC
T43	Procedure 1175 1180	chemo
T44	Procedure 1181 1190	radiation
T46	Negation 1222 1225	not
T47	Procedure 1263 1291	palliative radiation therapy
T48	Condition 1296 1318	symptomatic metastases
T49	Qualifier 1296 1307	symptomatic
T50	Temporal 1349 1401	>14 days prior the initiation of the study treatment
T51	Reference_point 1364 1401	the initiation of the study treatment
T52	Non-representable 1407 1469	Presence of evaluable (measureable or non-measurable) disease.
T53	Measurement 1474 1497	ECOG Performance Status
T54	Value 1501 1507	0 or 1
T55	Measurement 1544 1575	Absolute neutrophil count (ANC)
T56	Value 1576 1589	>1,500/microL
T57	Measurement 1594 1603	platelets
T58	Value 1604 1619	>100,000/microL
T59	Temporal 1621 1657	≤72 hours prior to initial treatment
T60	Reference_point 1640 1657	initial treatment
T62	Measurement 1661 1671	Hemoglobin
T63	Value 1672 1679	>9 g/dL
T64	Non-representable 1680 1773	(Note: Patients may be transfused or receive erythropoietin to maintain or exceed this level)
T65	Measurement 1776 1785	Bilirubin
T66	Value 1786 1791	< ULN
T67	Measurement 1794 1824	Alanine aminotransferase (ALT)
T68	Measurement 1829 1861	aspartate aminotransferase (AST)
T69	Value 1862 1898	≤2.5 times the upper limit of normal
T70	Condition 1905 1922	liver involvement
T71	Negation 1902 1904	no
T72	Context_Error 1905 1922	liver involvement
T74	Value 1926 1960	≤5 times the upper limit of normal
T75	Condition 1966 1984	liver involvement.
T77	Measurement 1986 1996	Creatinine
T78	Value 1997 2007	<2.0 mg/dL
T79	Measurement 2012 2032	creatinine clearance
T80	Value 2033 2043	>40 mL/min
T81	Qualifier 2066 2088	Cockcroft-Gault method
T82	Pregnancy_considerations 2091 2842	8. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and at least 6 months after the last dose of the study treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. Sexually active men must agree to use a medically acceptable form of birth control during treatment and at least 6 months after the last dose. If a female partner becomes pregnant during the course of the study the treating physician should be informed immediately.
T83	Value 2847 2856	>18 years
T84	Person 2860 2863	age
T85	Post-eligibility 2870 2984	Ability to understand the nature of this study, give written informed consent, and comply with study requirements.
T86	Post-eligibility 2990 3480	Patients entering this study must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing. An exception to this is when the national/local regulations prohibits some of the key activities of this research like the export of samples to third countries, storage of coded samples or global gene expression profiling without a pre-specified list of target genes. If tissue is not available, a patient will still be eligible for enrollment into the study
